Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2016-10-03 Capital/Financing Update
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Loan and Security Agreement involving borrowing $10 million and potential additional borrowing, along with details about warrants issued. There are no financial statements or comprehensive financial data presented, only a description of the financing arrangement and related terms. This fits the category of a Capital/Financing Update, as it reports on new financing activities and capital structure changes. The document length is 7322 characters, which is sufficient for a detailed announcement but does not constitute a full financial report like an Annual or Interim Report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-10-03 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2016, for Cidara Therapeutics, Inc. The key content is Item 7.01 Regulation FD Disclosure, which states that a slide presentation (Exhibit 99.1) will be presented in investor meetings. The document explicitly states that the slide presentation is attached as an exhibit and that the information is not deemed filed for certain regulatory purposes. The document is short (2741 characters) and primarily serves as an announcement of the presentation material rather than the presentation itself. According to the classification rules, a short document announcing or attaching a presentation for investor meetings fits best under Investor Presentation (IP). The document is not a full financial report, earnings release, or regulatory filing beyond the 8-K form itself. Therefore, the classification is Investor Presentation (IP) with high confidence.
2016-09-28 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the approval of compensation arrangements for executive officers in the event of employment termination or change in control transactions. It details severance and change of control benefits for executives, including the CEO. This type of disclosure relates to changes in management compensation and arrangements rather than a full annual or quarterly report, earnings release, or other financial report. It is not a proxy statement or remuneration report but rather a current event announcement about management compensation arrangements. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes in senior management or related arrangements. The document length and detail support this classification with high confidence.
2016-09-19 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which specifically details the resignation of the Chief Medical Officer and the appointment of an Acting Chief Medical Officer. This falls under the category of Board/Management Information (MANG) as it pertains to changes in senior management.
2016-09-01 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-08-11 English
8-K 2016-08-11
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated August 11, 2016, reporting the issuance of a press release with financial results for the second quarter ended June 30, 2016. The text explicitly states that the press release is attached as an exhibit and that the information is not filed as part of a formal report but rather a current report. The document length is short (3014 characters), and it primarily announces the release of financial results rather than containing the full financial statements or detailed analysis itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly financial results with key highlights only, not a full interim report or annual report.
2016-08-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.